Skip to main content

Research Repository

Advanced Search

All Outputs (174)

Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS) (2022)
Journal Article
Cotton, S., Devereux, G., Abbas, H., Briggs, A., Campbell, K., Chaudhuri, R., …Lipworth, B. J. (2022). Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials, 23(1), Article 307. https://doi.org/10.1186/s13063-022-06226-8

Background: Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity, mortality and healthcare costs. Beta blockers are well-established drugs widely used to treat cardiovascular conditions. Observational studies consiste... Read More about Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS).

Treatment of chronic cough: P2X3 receptor antagonists and beyond (2022)
Journal Article
Sykes, D. L., Zhang, M., & Morice, A. H. (2022). Treatment of chronic cough: P2X3 receptor antagonists and beyond. Pharmacology and Therapeutics, 237, Article 108166. https://doi.org/10.1016/j.pharmthera.2022.108166

For years chronic cough (CC) has presented an enormous physical, psychological, and social burden on those who experience it, with no approved pharmacological therapies to assuage their symptoms. With our improved understanding of the pathophysiologi... Read More about Treatment of chronic cough: P2X3 receptor antagonists and beyond.

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials (2022)
Journal Article
McGarvey, L. P., Birring, S. S., Morice, A. H., Dicpinigaitis, P. V., Pavord, I. D., Schelfhout, J., …Smith, J. A. (2022). Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet, 399(10328), 909-923. https://doi.org/10.1016/S0140-6736%2821%2902348-5

Background: Gefapixant is an oral P2X3 receptor antagonist that has previously shown efficacy and safety in refractory chronic cough and unexplained chronic cough. We therefore aim to confirm the efficacy and safety of gefapixant in participants with... Read More about Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough (2022)
Journal Article
McGarvey, L., Smith, J. A., Morice, A., Birring, S. S., Chung, K. F., Dicpinigaitis, P. V., …Gomez, J. C. (2022). A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough. Lung, https://doi.org/10.1007/s00408-022-00592-5

Introduction: To determine the optimal dose of sivopixant, a highly selective P2X3 receptor antagonist, for refractory or unexplained chronic cough (RCC/UCC). Methods: In this phase 2b, randomized, double-blind, placebo-controlled, parallel-group, mu... Read More about A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough.

European respiratory society guidelines on the diagnosis and treatment of chronic cough in adults and children (2021)
Journal Article
Morice, A. H., Millqvist, E., Bieksiene, K., Birring, S. S., Dicpinigaitis, P., Ribas, C. D., …Zacharasiewicz, A. (2021). European respiratory society guidelines on the diagnosis and treatment of chronic cough in adults and children. Pulmonologiya, 31(4), 418-438. https://doi.org/10.18093/0869-0189-2021-31-4-418-438

These guidelines incorporate the recent advances in chronic cough pathophysiology, diagnosis and treatment. The concept of cough hypersensitivity has allowed an umbrella term that explains the exquisite sensitivity of patients to external stimuli suc... Read More about European respiratory society guidelines on the diagnosis and treatment of chronic cough in adults and children.

Chronic cough: new insights and future prospects (2021)
Journal Article
Morice, A., Dicpinigaitis, P., McGarvey, L., & Birring, S. S. (2021). Chronic cough: new insights and future prospects. European Respiratory Review, 30(162), Article 210127. https://doi.org/10.1183/16000617.0127-2021

Chronic cough is defined in adults as a cough that lasts for ≥8 weeks. When it proves intractable to standard-of-care treatment, it can be referred to as refractory chronic cough (RCC). Chronic cough is now understood to be a condition of neural dysr... Read More about Chronic cough: new insights and future prospects.

Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough (2021)
Journal Article
Ludbrook, V. J., Hanrott, K. E., Kreindler, J. L., Marks-Konczalik, J. E., Bird, N. P., Hewens, D. A., …Smith, J. (2021). Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough. ERJ Open Research, 7(3), Article 00269-2021. https://doi.org/10.1183/23120541.00269-2021

Objective Airway sensory nerves involved in the cough reflex are activated by adenosine triphosphate (ATP) agonism of P2X purinoceptor 3 (P2X3) receptors. Transient receptor potential vanilloid 4 (TRPV4) channel activation causes ATP release from air... Read More about Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough.

The Cough Reflex: The Janus of Respiratory Medicine (2021)
Journal Article
Sykes, D. L., & Morice, A. H. (2021). The Cough Reflex: The Janus of Respiratory Medicine. Frontiers in Physiology, 12, Article 684080. https://doi.org/10.3389/fphys.2021.684080

In clinical practice, we commonly face adversity when encountering dysfunction of the cough reflex. Similar to ancient Roman deity Janus, it often presents with one of two opposing “faces”. Continual aberrant activation of the cough reflex, also know... Read More about The Cough Reflex: The Janus of Respiratory Medicine.

Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: A randomised, placebo-controlled, crossover phase 2a study (2021)
Journal Article
Morice, A., Smith, J. A., McGarvey, L., Birring, S. S., Parker, S. M., Turner, A., …Friedrich, C. (2021). Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: A randomised, placebo-controlled, crossover phase 2a study. European respiratory journal, 58(5), Article 2004240. https://doi.org/10.1183/13993003.04240-2020

Background. ATP acting via P2X3 receptors is an important mediator of refractory chronic cough (RCC). This phase 2a double-blinded crossover study assessed the safety, tolerability and efficacy of eliapixant (BAY 1817080), a selective P2X3 receptor a... Read More about Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: A randomised, placebo-controlled, crossover phase 2a study.

Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant (2021)
Journal Article
Morice, A. H., Birring, S. S., Smith, J. A., McGarvey, L. P., Schelfhout, J., Martin Nguyen, A., …Sher, M. R. (2021). Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant. Lung, 199(2), 121-129. https://doi.org/10.1007/s00408-021-00437-7

Purpose: This analysis assesses clinical characteristics of patients with refractory chronic cough (RCC) or unexplained chronic cough (UCC) enrolled in a phase 2 study to better understand this patient population. Methods: Patients with RCC/UCC lasti... Read More about Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.

Domiciliary Cough Monitoring for the Prediction of COPD Exacerbations (2021)
Journal Article
Crooks, M. G., den Brinker, A. C., Thackray-Nocera, S., van Dinther, R., Wright, C. E., & Morice, A. H. (2021). Domiciliary Cough Monitoring for the Prediction of COPD Exacerbations. Lung, 199(2), 131-137. https://doi.org/10.1007/s00408-021-00435-9

Introduction: Acute exacerbations of COPD (AE-COPD) are a leading cause of health service utilisation and are associated with morbidity and mortality. Identifying the prodrome of AE-COPD by monitoring symptoms and physiological parameters (telemonito... Read More about Domiciliary Cough Monitoring for the Prediction of COPD Exacerbations.

Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It? (2021)
Journal Article
Sykes, D. L., Holdsworth, L., Jawad, N., Gunasekera, P., Morice, A. H., & Crooks, M. G. (2021). Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It?. Lung, 199(2), 113-119. https://doi.org/10.1007/s00408-021-00423-z

© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature. The enduring impact of COVID-19 on patients has been examined in recent studies, leading to the description of Long-COVID. We report the l... Read More about Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It?.

Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production (2020)
Journal Article
Atkinson, S. K., Morice, A. H., & Sadofsky, L. R. (2020). Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production. ERJ Open Research, 6(4), Article 00159-2020. https://doi.org/10.1183/23120541.00159-2020

Human rhinovirus (RV) is the most common cause of upper respiratory tract infection (URTI) and chronic airway disease exacerbation. Cough is present in 50–80% of URTI cases, accompanied by heightened airway hypersensitivity, yet no effective treatmen... Read More about Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production.